FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileIncyte Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
INCY
Incyte Corporation Stock AnalysisComprehensive stock analysis for Incyte Corporation (INCY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisINCY
INCY
Incyte Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
INCY
  1. Home
  2. Stocks
  3. Incyte Corporation

Incyte Corporation

🇺🇸INCY•NASDAQ

Incyte Corporation

🇺🇸INCY•NASDAQ
Market cap
$24.51B
Sentiment

Your view on INCY

Mkt Cap
$24.51B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Incyte Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Herve Hoppenot
Headquarters
1801 Augustine Cut-Off, Wilmington, DE, US
Industry
Biotechnology
Sector
Healthcare
CEO
Herve Hoppenot
Headquarters
1801 Augustine Cut-Off, Wilmington, DE, US
Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.

The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.

In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma.

Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer.

It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.

The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Incyte Corporation from FRC's valuation model, read against the market price. INCY last traded at $120.27, 57.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Incyte Corporation. Starting points for Incyte Corporation: P/E 57.4, EPS $1.98, beta 0.78 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Incyte Corporation. Incyte Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Incyte Corporation. Trailing twelve-month EPS for Incyte Corporation stands at $1.98. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$131.90

average of 20 firms, last 12 months

 

$131.90

Low $90.00

Median $134.50

High $157.00

 

Analyst Ratings

Hold19 firms, last 12 months
  • Strong Buy0
  • Buy9
  • Hold10
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.92$1.70$3.22$8.08
Low estimate$1.74$1.59$2.51$7.48
High estimate$2.23$1.81$4.05$8.72
No. of analysts1351516
Year-ago EPS$1.80$1.81$6.41—
Growth+6.8%-6.3%-49.8%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.56B$1.38B$6.05B$6.26B
Low estimate$1.53B$1.33B$5.95B$6.00B
High estimate$1.60B$1.41B$6.10B$6.60B
No. of analysts1361818
Year-ago revenue$1.51B$1.27B$5.14B—
Growth+3.4%+8.5%+17.7%—
Recent analyst actions15 rating and price-target changes, latest Nov 17, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Incyte Corporation. Incyte Corporation has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold INCY20 companies · 8 funds
Compare INCY with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • AVBPArriVent BioPharma, Inc. Common StockBiotechnology$598M
  • CGEMCullinan Therapeutics, Inc.Biotechnology$617M
  • EXELExelixis, Inc.Biotechnology$16.9B
  • GMABGenmab A/SBiotechnology$31.8B
  • LEGNLegend Biotech CorporationBiotechnology$3.0B
  • LGNDLigand Pharmaceuticals IncorporatedBiotechnology$6.0B
  • NRIXNurix Therapeutics, Inc.Biotechnology$1.6B
  • REGNRegeneron Pharmaceuticals, Inc.Biotechnology$98.5B

More Biotechnology companies

  • SNBIFSanBio Company LimitedOTC$1.3B
  • SNDXSyndax Pharmaceuticals, Inc.NASDAQ$822M
  • SNGXSoligenix, Inc.NASDAQ$7M
  • SNNAQSienna Biopharmaceuticals, Inc.OTC$3,091
  • SNTISenti Biosciences, Inc.NASDAQ$4M
  • SOLTFNxera Pharma Co., Ltd.OTC$492M
  • SONA.CNSona Nanotech Inc.CNQ$49M
  • SPHDFSanthera Pharmaceuticals Holding AGOTC$295M
  • SPHRFStarpharma Holdings LimitedOTC$134M
  • SPHRYStarpharma Holdings LimitedOTC$141M
  • SPL.AXStarpharma Holdings LimitedASX
  • SPRBSpruce Biosciences, Inc.NASDAQ$121M

ETFs holding Incyte Corporation

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.03%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
  • VBVanguard Small-Cap ETF$76.9B in assets0.26%
  • IVViShares Core SP 500 ETF$852.9B in assets0.03%
  • IDNAiShares Genomics Immunology and Healthcare ETF$352M in assets3.50%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.50%
  • FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets3.26%
  • PBEInvesco Biotechnology & Genome ETF$438M in assets2.58%

Largest holders first, then the funds most concentrated in INCY.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Incyte Corporation, and how their positions are changing. At a $24.51B market value, institutional positions materially move Incyte Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Incyte Corporation executives and directors. Shares of Incyte Corporation have traded between $53.56 and $109.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Incyte Corporation. Incyte Corporation is a $24.51B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Incyte Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Incyte Corporation. Coverage tracks Incyte Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Incyte Corporation.

INCY Analysis
Strong
Past5
Growth5
Health5
Profit4
Value3

News

Latest Market News